Start with the research question, not the biggest funding pool
US biotech and biomedical R&D funding includes small-business research grants, mission-specific development opportunities and challenge-based research programs. The useful shortlist depends on who will apply, what the project must prove and which agency supports that question. A university laboratory, a small business and a company with an existing award do not automatically share the same application route.
This guide helps founders and research teams organize those routes before building an application. It is a source-dated program directory, not a finding that a particular business qualifies. For broader funding mechanisms, see the SBIR and STTR funding guide.
Current biomedical funding routes to investigate
The following official pages were reviewed on October 1, 2026, US Eastern time. NIH confirms that SBIR, STTR and related pilot programs were reauthorized on April 13, 2026 through September 30, 2031. That does not make every solicitation open or every research budget available. NIH reauthorization notice.
| Route | Research or applicant focus | First item to record |
|---|---|---|
| NIH, CDC and FDA Parent SBIR, PA-27-100 | US small businesses developing scientific innovations | Participating awarding component and the applicable research phase |
| NIH Parent STTR, PA-27-102 | US small businesses partnering with a nonprofit research institution | Company applicant, research partner and proposed responsibilities |
| NIH Phase IIB Strategic Breakthrough Award, PA-27-101 | A separate follow-on research route | Prior-award and project conditions in the full announcement |
| NIH Commercialization Readiness Pilot, PAR-27-098 | A distinct commercialization-readiness route | Required award history and supported activities |
| BARDA ImmuneChip+ | Immune-system tissue models for medical-countermeasure development | Fit with the specified health-security research objective |
| BARDA Single Shield Prize | Single-administration vaccine platforms for pandemic influenza A(H5N1) | Prize-stage requirements and the current entry deadline |
| ARPA-H programs and Mission Office ISOs | Research addressing a defined health challenge or mission area | Whether a program-specific or Mission Office route applies |
NIH SBIR: a company-led research application
The current PA-27-100 opportunity record identifies small businesses as applicants and describes feasibility through later R&D toward a commercial product. Record the exact notice number rather than simply writing “NIH grant” in a spreadsheet. Institute fit, project scope and application instructions belong to the full announcement.
NIH STTR: keep the applicant and research partner distinct
The PA-27-102 opportunity record describes a small business working with a nonprofit research institution. A university connection can matter, but it is not a substitute for confirming the applicant and collaboration requirements. Preserve the proposed work allocation and open partnership questions alongside the opportunity.
NIH follow-on routes: do not treat every announcement as a first application
NIH's current directory also lists the Phase IIB Strategic Breakthrough Award and Commercialization Readiness Pilot. Those are separate routes to inspect, not interchangeable names for the parent SBIR application. The directory shows standard receipt dates with weekend and federal-holiday adjustments. A notice's expiration date is not the same as your selected application deadline. NIH current SBIR and STTR announcements.
BARDA: specific health-security work, not general biotech funding
ImmuneChip+ describes immune-system microphysiological models and states a September 28, 2028 closing date. BARDA's partnering directory lists the Single Shield Prize as open with a January 15, 2027 closing date. Verify the underlying solicitation or official prize rules before scheduling a submission. A promising oncology or laboratory-software project may still fall outside these specific objectives.
ARPA-H: separate the program route from the small-business label
The ARPA-H opportunities directory lists program opportunities and rolling Mission Office ISOs. On review, its small-business section explicitly reported no open opportunities. Do not present a named ARPA-H program as an open SBIR round. Mission Office submissions start with a Solution Summary and require agency feedback before a full proposal, according to that directory.
Build a six-field biomedical funding shortlist
A short evidence-led list is easier to act on than a collection of agency names. Give each candidate six fields:
- Applicant: the legal organization that would submit, plus required collaborators.
- Question: the scientific or development uncertainty the project addresses.
- Stage: work already completed and the next milestone to demonstrate.
- Evidence: existing results, methods, facilities and documented gaps.
- Instrument: grant, contract, prize or other mechanism stated in the opportunity.
- Clock: actual receipt deadline, registration work and internal review dates.
Add a status of investigate, confirmed route, waiting for clarification or not relevant. “Confirmed route” means the team has checked the published requirements; it does not mean an award or regulatory outcome is likely. Use the funding-deadline workflow to keep notices and next actions connected.
Worked example: a diagnostic startup with a university collaborator
This is a synthetic organizational example. A startup has a bench prototype and a university collaborator, but no completed clinical validation. Its next proposed project compares prototype performance under defined laboratory conditions.
The team creates separate SBIR and STTR records, attaches the available results and asks who would perform each research task. It flags institute fit and collaboration terms as unverified. It excludes the influenza-vaccine prize because its diagnostic project does not match that objective. ARPA-H remains a separate mission-fit inquiry, not a presumed small-business application.
The deliverable is a smaller shortlist with visible unanswered questions. Nothing in this example establishes scientific merit, eligibility, clinical readiness or approval.
Keep opportunities, evidence and conversations together
Use Finta CRM to organize agency contacts, partners and next steps. Keep supplied research materials in Documents, and ask Aurora to help prepare an evidence summary or clarification questions for review. The application remains in the agency's supported system; Finta does not award funding or provide a scientific assessment.
Methodology and limits
Finta Editorial Team selected primary federal sources with distinct applicant or research roles. This is not a comprehensive inventory or ranking. We did not submit applications, contact program officers or test approval outcomes. Agency budgets, deadlines, participating components and award conditions can change. Confirm the current notice and project-specific requirements directly before applying.